Cholinergic inputs to the rat medial prefrontal cortex mediate potentiation of the cardiovascular defensive response by the anxiogenic benzodiazephine receptor partial inverse agonist FG 7142.
Consistent with its putative anxiogenic actions, administration of the benzodiazepine receptor partial inverse agonist FG 7142 has been shown to potentiate defensive-like cardiovascular reactivity to an acoustic stimulus in the rat, an effect that appears to be mediated by the basal forebrain cholinergic system. The present studies tested the hypothesis that the basal forebrain cholinergic projections to the medial prefrontal cortex, an area that has been implicated in both anxiety and autonomic control, may be a relevant pathway underlying this response potentiation. Infusions of the muscarinic receptor agonist carbachol into the medial prefrontal cortex, but not into the lateral prefrontal cortex or the basolateral amygdala, mimicked the effects of systemically administered FG 7142 on the cardioacceleratory response. Infusions of the muscarinic antagonist atropine blocked this effect, as well as the response-potentiating actions of FG 7142. The effects of FG 7142 were also blocked by lesions of the cholinergic inputs to the medial prefrontal cortex produced by local infusions of the immunotoxin 192 immunoglobulin G-saporin into this area. These findings indicate that cholinergic activation of the medial prefrontal cortex is sufficient to enhance the cardioacceleratory defensive response, and that cholinergic inputs to the medial prefrontal cortex are necessary for the response-potentiating effects of FG 7142. These results are consistent with a recent neurobiological model of anxiety and autonomic control that attributes the enhanced processing of anxiety-related stimuli and contexts to increases in activity in cortical cholinergic inputs.
Hart
S
S
Department of Psychology and Neuroscience Program, The Ohio State University, Columbus 43210, USA.
Sarter
M
M
Berntson
G G
GG
D000818:Animals; D001007:Anxiety / Q000139:chemically induced*; D001285:Atropine / Q000494:pharmacology; D002243:Carbolines / Q000494:pharmacology; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects; D018678:Cholinergic Agents / Q000494:pharmacology; D002799:Cholinergic Fibers / Q000502:physiology*; D004924:Escape Reaction / Q000502:physiology*; D058785:GABA-A Receptor Agonists; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D009435:Synaptic Transmission / Q000502:physiology
D002243:Carbolines; D018678:Cholinergic Agents; D058785:GABA-A Receptor Agonists; D018727:Muscarinic Antagonists; C035874:FG 7142; D001285:Atropine